Vol 7, No 3 (2022)
Invited editorial
Published online: 2022-07-28
From cardiovascular prevention to treatment of critically ill COVID-19 patients
1
Medical Research Journal 2022;7(3):187-189.
Abstract
-
References
- Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA. 2018; 319(15): 1566–1579.
- Navarese EP, Andreotti F, Raggi P, et al. Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a review. Eur Heart J Cardiovasc Pharmacother. 2019; 5(1): 47–54.
- Mora S, Ridker PM. Justification for the use of statins in primary prevention: an intervention trial evaluating rosuvastatin (JUPITER) - can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol. 2006; 97(2A): 33A–41A.
- Sun L, Zou L, Chen M, et al. Meta-analysis of statin therapy in maintenance dialysis patients. Ren Fail. 2015; 37(7): 1149–1156.
- Obońska K, Kasprzak M, Sikora J, et al. The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial. Trials. 2017; 18(1): 316.
- Obońska K, Kasprzak M, Tymosiak K, et al. Low dose of ROSuvastatin in combination with EZEtimibe effectively and permanently reduce low density lipoprotein cholesterol concentration independently of timing of administration (ROSEZE): A randomized, crossover study - preliminary results. Cardiol J. 2021; 28(1): 58–66.
- Sut A, Chiżyński K, Różalski M, et al. Dietary intake of omega fatty acids and polyphenols and its relationship with the levels of inflammatory markers in men with chronic coronary syndrome after percutaneous coronary intervention. Kardiol Pol. 2020; 78(2): 117–123.
- De Luca L, Corsini A, Uguccioni M, et al. Statins plus ezetimibe in the era of proprotein convertase subtilisin/ kexin type 9 inhibitors. Kardiol Pol. 2020; 78(9): 850–860.
- Chlebus K, Cybulska B, Dobrowolski P, et al. Effectiveness and safety of PCSK9 inhibitor therapy in patients with familial hypercholesterolemia within a therapeutic program in Poland: Preliminary multicenter data. Cardiol J. 2022; 29(1): 62–71.
- Navarese EP, Kolodziejczak M, Schulze V, et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med. 2015; 163(1): 40–51.
- Geng Q, Li X, Sun Q, et al. Efficacy and safety of PCSK9 inhibition in cardiovascular disease: a meta-analysis of 45 randomized controlled trials. Cardiol J. 2022; 29(4): 574–581.
- Schuster S, Rubil S, Endres M, et al. Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice. Sci Rep. 2019; 9(1): 11079.
- Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A. 2003; 100(3): 928–933.
- Walley KR, Thain KR, Russell JA, et al. PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Sci Transl Med. 2014; 6(258): 258ra143.
- Navarese EP, Kołodziejczak M, Petrescu A, et al. Role of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with coronary artery disease undergoing percutaneous coronary intervention. Expert Rev Cardiovasc Ther. 2018; 16(6): 419–429.
- Walley KR, Thain KR, Russell JA, et al. PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Sci Transl Med. 2014; 6(258): 258ra143.
- Ruscica M, Ferri N, Fogacci F, et al. Brisighella Heart Study Group. Circulating levels of proprotein convertase subtilisin/kexin Type 9 and arterial stiffness in a large population sample: data from the brisighella heart study. J Am Heart Assoc. 2017; 6(5).
- Ruscica M, Tokgözoğlu L, Corsini A, et al. PCSK9 inhibition and inflammation: A narrative review. Atherosclerosis. 2019; 288: 146–155.
- Rasmussen P, Yandrapalli S, Aronow W. Statin therapy for primary cardiovascular prevention in adults older than 75 years. Kardiol Pol. 2021; 79(1): 18–24.
- Adamski P, Adamska U, Ostrowska M, et al. New directions for pharmacotherapy in the treatment of acute coronary syndrome. Expert Opin Pharmacother. 2016; 17(17): 2291–2306.
- Szymański FM, Mickiewicz A, Dzida G, et al. Management of dyslipidemia in Poland: Interdisciplinary Expert Position Statement endorsed by The Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. The fourth declaration of Sopot. Cardiol J. 2022; 29(1): 1–26.
- Świątkiewicz I, Magielski P, Kubica J. C-reactive protein as a risk marker for post-infarct heart failure over a multi-year period. Int J Mol Sci. 2021; 22(6).
- Świątkiewicz I, Magielski P, Kubica J, et al. Enhanced inflammation is a marker for risk of post-infarct ventricular dysfunction and heart failure. Int J Mol Sci. 2020; 21(3).
- Swiatkiewicz I, Kozinski M, Magielski P, et al. Usefulness of C-reactive protein as a marker of early post-infarct left ventricular systolic dysfunction. Inflamm Res. 2012; 61(7): 725–734.
- Swiatkiewicz I, Kozinski M, Magielski P, et al. Value of C-reactive protein in predicting left ventricular remodelling in patients with a first ST-segment elevation myocardial infarction. Mediators Inflamm. 2012; 2012: 250867.
- Kubica A, Obońska K, Fabiszak T, et al. Adherence to antiplatelet treatment with P2Y12 receptor inhibitors. Is there anything we can do to improve it? A systematic review of randomized trials. Curr Med Res Opin. 2016; 32(8): 1441–1451.
- Pietrzykowski Ł, Kasprzak M, Michalski P, et al. The influence of patient expectations on adherence to treatment regimen after myocardial infarction. Patient Educ Couns. 2022; 105(2): 426–431.
- Pietrzykowski Ł, Kasprzak M, Michalski P, et al. Therapy discontinuation after myocardial infarction. J Clin Med. 2020; 9(12).
- Kubica A, Kasprzak M, Siller-Matula J, et al. Time-related changes in determinants of antiplatelet effect of clopidogrel in patients after myocardial infarction. Eur J Pharmacol. 2014; 742: 47–54.
- Pietrzykowski Ł, Kasprzak M, Michalski P, et al. Medication adherence and its determinants in patients after myocardial infarction. Sci Rep. 2020; 10(1): 12028.
- Kubica A, Kosobucka A, Fabiszak T, et al. Assessment of adherence to medication in patients after myocardial infarction treated with percutaneous coronary intervention. Is there a place for newself-reported questionnaires? Curr Med Res Opin. 2019; 35(2): 341–349.
- Kubica A, Kasprzak M, Obońska K, et al. Discrepancies in assessment of adherence to antiplatelet treatment after myocardial infarction. Pharmacology. 2015; 95(1-2): 50–58.
- Kosobucka A, Michalski P, Pietrzykowski Ł, et al. The impact of readiness to discharge from hospital on adherence to treatment in patients after myocardial infarction. Cardiol J. 2022; 29(4): 582–590.
- Kubica A, Michalski P, Kasprzak M, et al. Two different approaches to assess adherence to medication in Polish cohort of the EUROASPIRE V registry. Medical Research Journal. 2022.
- Atar D, Langset G, Tonstad S. Do we need new lipid-lowering agents in the era of PCSK9 inhibitors? Recent advances. Kardiol Pol. 2022 [Epub ahead of print].
- Ridker PM. From c-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res. 2016; 118(1): 145–156.
- Angriman F, Ferreyro B, Burry L, et al. Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context. Lancet Respir Med. 2021; 9(6): 655–664.
- Kubica J, Podhajski P, Magielski P, et al. IMPACT of PCSK9 inhibition on clinical outcome in patients during the inflammatory stage of the SARS-COV-2 infection: Rationale and protocol of the IMPACT-SIRIO 5 study. Cardiol J. 2022; 29(1): 140–147.